New combo therapy aims to wipe out rectal cancer before surgery
NCT ID NCT07478731
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug SHR-1701 to standard chemoradiotherapy can completely eliminate tumors in people with advanced rectal cancer before they have surgery. About 48 adults aged 18-75 with a specific type of rectal cancer will receive the treatment over several cycles, followed by tumor removal. The main goal is to see if no cancer cells remain after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRC (COLORECTAL CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- A new radiation combo may spare the rectum in early cancer
- Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
- Metabolic MRI may reveal hidden cancer responses and spare patients from surgery
- Can a beetroot drink spot dangerous surgical leaks before they turn deadly?